Table 5 Top 10 articles by LC
From: Bibliometric analysis of residual cardiovascular risk: trends and frontiers
Rank | Title | Journal | Author | Year | LC | GC |
|---|---|---|---|---|---|---|
1 | Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy | New Engl J Med | Boden WE | 2011 | 153 | 1923 |
2 | The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient | Diabetes Vasc Dis Res | Fruchart JC | 2008 | 42 | 212 |
3 | Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges | Curr Atheroscler Rep | Sampson UK | 2012 | 41 | 198 |
4 | HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial | Lancet | Ridker PM | 2010 | 39 | 178 |
5 | A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies | J Am Coll Cardiol | TSIMIKAS S | 2017 | 34 | 405 |
6 | Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study | Circulation | Mora S | 2012 | 33 | 108 |
7 | Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) | Circulation | Khera AV | 2014 | 31 | 229 |
8 | Residual macrovascular risk in 2013: what have we learned? | Cardiovasc Diabetol | Fruchart JC | 2014 | 31 | 124 |
9 | Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study | Am Heart J | Pradhan AD | 2018 | 31 | 179 |
10 | Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis | Atherosclerosis | Bruckert E | 2010 | 26 | 216 |